Can diabetes drugs like Ozempic help prevent addiction?
Yes. In a large study of US veterans with type 2 diabetes, people who started a GLP-1 drug like Ozempic had a lower risk of developing substance use disorders than people who started a different diabetes drug. Overall, their risk dropped by about 14 percent.
GLP-1 receptor agonists are medicines first made to treat type 2 diabetes and obesity. You may know them by brand names like Ozempic, Wegovy, or Victoza. They include drugs such as semaglutide, liraglutide, and dulaglutide. These medicines help control blood sugar and reduce appetite. But growing evidence suggests they may also affect the brain, and that is where this study gets interesting.
A substance use disorder is the medical term for addiction. It means a person keeps using a substance like alcohol, opioids, or cannabis even when it harms their life. This study asked a simple question: could these popular metabolic drugs also lower the chance of falling into addiction?
What the data show
The study followed 606,434 US veterans with type 2 diabetes for up to three years. Researchers compared people who started a GLP-1 drug with people who started a different diabetes drug called an SGLT-2 inhibitor. They looked at two groups: people with no history of addiction, and people who already had a substance use disorder.
For people with no history of addiction, the GLP-1 group had lower risks across the board. Their risk of an alcohol use disorder fell by 18 percent (hazard ratio 0.82). Opioid use disorder risk fell by 25 percent (0.75), and cannabis use disorder risk fell by 14 percent (0.86). Cocaine, nicotine, and other substance disorders also dropped. When all of these were combined, the GLP-1 group had about a 14 percent lower risk overall (0.86).
The results were even stronger for people who already had a substance use disorder. In this group, GLP-1 use was linked to 31 percent fewer drug-related emergency room visits (0.69) and 26 percent fewer hospital stays (0.74). It was also tied to fewer drug overdoses (0.61) and a sharp drop in substance-related deaths (0.50), meaning roughly half the risk compared with the other drug.
Dr. Kumar’s Take
I find this study fascinating because it points to something bigger than diabetes. We have known for a while that GLP-1 drugs do more than lower blood sugar. They seem to act on the brain’s reward and craving system, the same wiring that drives addiction. That may explain why people on these drugs report less interest not just in food, but sometimes in alcohol too.
That said, I want to be honest about the limits. This is observational research, which means it can show a strong link but cannot prove that the drug caused the lower risk. These were also mostly older male veterans, so the findings may not apply to everyone. Still, the size of this study and how consistent the results were across so many different substances make it hard to ignore. This is a signal worth taking seriously.
How strong is the evidence?
The researchers used a careful method called target trial emulation. In plain terms, they used real medical records to mimic the structure of a randomized trial as closely as possible. They compared new users of one drug against new users of another similar drug, which helps reduce some common biases.
They also ran a second check. Instead of only looking at who started a drug, they looked at who actually kept taking it. The results pointed in the same direction. That kind of consistency adds confidence. Even so, the design cannot rule out every hidden factor, so these results should be seen as a strong clue rather than final proof.
Practical Takeaways
- If you take a GLP-1 drug like Ozempic for diabetes or weight, know that researchers are studying possible benefits for the brain, but these uses are not yet approved.
- Do not start or stop any medication on your own based on this study, and always talk with your doctor about your full health picture first.
- If you or someone you love struggles with addiction, these findings are promising but do not replace proven treatments like counseling and established medications.
- Ask your doctor about ongoing trials if you are curious, since this research is still early and being actively tested.
Related Studies and Research
- GLP-1 drugs like Ozempic linked to better breast cancer survival
- Teen cannabis use linked to higher risk of psychotic and mood disorders
- Omega-3 fatty acids and type 2 diabetes risk: what the latest research reveals
- Starting tirzepatide early beats stacking other diabetes drugs
FAQs
How might Ozempic and similar drugs affect addiction?
Scientists believe GLP-1 drugs work on the brain’s reward and craving circuits, not just the gut. These are the same pathways that drive the urge to drink, smoke, or use drugs. By dampening these signals, the medicines may reduce cravings for substances the same way they reduce cravings for food. This is still a developing area of science, and researchers are working to understand exactly how it happens.
Can I take a GLP-1 drug just to help with drinking or drug use?
Not right now. These drugs are approved to treat type 2 diabetes and obesity, not addiction. While this study and others are encouraging, using a medicine outside its approved purpose should only happen under a doctor’s care. If you are struggling with alcohol or drug use, the most reliable help still comes from counseling and treatments already proven to work for addiction.
Why were the results stronger in people who already had a substance use disorder?
In that group, GLP-1 use was tied to fewer emergency visits, fewer hospital stays, fewer overdoses, and fewer deaths. One reason the numbers may look larger is that people with an existing disorder start at higher risk, so any reduction shows up more clearly. It suggests these drugs might help not only prevent addiction but also reduce its most dangerous outcomes. This is an important reason researchers want to test the idea in formal trials.
Bottom Line
In a study of more than 600,000 US veterans with type 2 diabetes, GLP-1 drugs like Ozempic were linked to a lower risk of developing substance use disorders, including those tied to alcohol, opioids, and cannabis, with an overall drop of about 14 percent. Among people who already had an addiction, the drugs were tied to fewer emergencies, overdoses, and deaths. These findings cannot prove cause and effect, but they hint at a powerful new role for these medicines in addiction care, and they make a strong case for more research.
